Circulating biomarkers for diagnosis, prognosis and treatment response prediction in cancer - Part a (International Review of Cell and Molecular Biology)

個数：

Circulating biomarkers for diagnosis, prognosis and treatment response prediction in cancer - Part a (International Review of Cell and Molecular Biology)

Galluzzi, Lorenzo (EDT)/ Spada, Sheila (EDT)

ウェブストア価格 ¥48,457（本体¥44,052）
Academic Press Inc（2025/05発売）
外貨定価 US$ 239.00
ポイント 440pt

在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
通常6～9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
【重要ご説明事項】
1. 納期遅延や、ご入手不能となる場合がございます。
2. 複数冊ご注文の場合、分割発送となる場合がございます。
3. 美品のご指定は承りかねます。

●3Dセキュア導入とクレジットカードによるお支払いについて

【入荷遅延について】
世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。

◆画像の表紙や帯等は実物とは異なる場合があります。

◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
また、洋書販売価格は、ご注文確定時点での日本円価格となります。
ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。

製本 Hardcover:ハードカバー版／ページ数 274 p.
言語 ENG
商品コード 9780443345296
DDC分類 616.994

Full Description

Circulating Biomarkers for Diagnosis, Prognosis and Treatment Response Prediction in Cancer Patients, Part A, Volume 391 delves into the crucial role of circulating biomarkers in cancer diagnosis and treatment monitoring. Specific chapters in this new release include Circulating biomarkers for diagnosis and response to therapies in cancer patients, Identification of circulating tumor DNA as a biomarker for diagnosis and response to therapies in cancer patients, Identification of cell-free circulating epigenomic biomarkers for early diagnosis and response to therapies in breast cancer patients, Expanding frontiers in liquid biopsy-discovery and validation of circulating biomarkers in renal cell carcinoma and bladder cancer, and much more.

This comprehensive work explores the various types of biomarkers, their significance in early cancer detection, prognostication, and evaluation of therapeutic responses. It covers cutting-edge research on circulating tumor cells, cell-free DNA, exosomes, and other biomarkers that can revolutionize cancer management. Additionally, it discusses the challenges, advancements, and future prospects of utilizing circulating biomarkers in personalized cancer care.

Preface
Sheila Spada and Lorenzo Galluzzi
1. Circulating biomarkers for diagnosis and response to therapies in cancer patients
Natália Marcéli Stefanes, Maria Eduarda Cunha-Silva, Lisandra de Oliveira Silva,
Laura Otto Walter, Maria Cláudia Santos-Silva, and Manas Ranjan Gartia
2. Identification of circulating tumor DNA as a biomarker for diagnosis and response to therapies in cancer patients
Ronan W. Hsieh, Lynn K. Symonds, Jason Siu, and Stacey A. Cohen
3. Identification of cell-free circulating epigenomic biomarkers for early diagnosis and response to therapies in breast cancer patients
Pooja Ratre, Suresh Thareja, Pradyumna Kumar Mishra
4. Expanding frontiers in liquid biopsy-discovery and validation of circulating biomarkers in renal cell carcinoma and bladder cancer
Sabareeswaran Krishnan, Shruthi Kanthaje, Punchappady Devasya Rekha,
M. Mujeeburahiman, and Chandrahas Koumar Ratnacaram
5. Interleukin 10: Bridging the chasms in the immune landscape of multiple myeloma
Queenie Fernandes, Abdul W. Ansari, Karama Makni-Maalej, Maysaloun Merhi,
Said Dermime, Aamir Ahmad, and Shahab Uddin
6. Nectin-4: A promising prognostic marker and therapeutic target in cancer
Shilpa Kuttikrishnan, Kirti S. Prabhu, Ummu Habeeba, Zahwa Mariyam, Queenie Fernandes, Mohsin Maqbool, Omar M. Khan, Ajaz A. Bhat, and Shahab Uddi